BREAST
Atezolizumab             
Pertuzumab              
Trastuzumab            

PDAC: no drugs

NSCLC
Bevacizumab
Nivolumab
Pembrolizumab
Ramucirumab
Necitumumab
Durvalumab
Atezolizumab            BREAST

SCLC
Bevacizumab             NSCLC
Nivolumab               NSCLC
Pembrolizumab           NSCLC
Ramucirumab             NSCLC
Necitumumab             NSCLC
Durvalumab              NSCLC
Atezolizumab            NSCLC

GASTRIC
Trastuzumab             BREAST
Pembrolizumab           SCLC, NSCLC
Ramucirumab             SCLC, NSCLC


MELANOMA:
Ipilimumab                   HCC
Nivolumab                    SCLC, NSCLC
Pembrolizumab 
Talimogene laherparepvec     STRUCTURE NA
Interferon alfa-2b 
Peginterferon alfa-2b 
Aldesleukin 

GLIOMA
Bevacizumab

COLORECTAL
Cetuximab
Bevacizumab             SCLC, NSCLC
Panitumumab 
Nivolumab               SCLC, NSCLC
Pembrolizumab           SCLC, NSCLC
Ramucirumab             SCLC, NSCLC

ENDOMETRIAL
Pembrolizumab           SCLC, NSCLC

HCC
Ipilimumab 
Nivolumab                    SCLC, NSCLC, COLORECTAL
Pembrolizumab                SCLC, NSCLC, COLORECTAL
Ramucirumab                  SCLC, NSCLC
Atezolizumab                 BREAST

ACUTE LEUKEMIA
Gemtuzumab ozogamicin

CHRONIC myeloid leukemia
Gemtuzumab ozogamicin

BLADDER
Nivolumab HCC
Pembrolizumab HCC
Durvalumab SCLC, NSCLC
Avelumab 
Atezolizumab BREAST, SCLC, NSCLC
Enfortumab vedotin 

RCC
Bevacizumab  SCLC, NSCLC, GLIOMA
Ipilimumab  MELANOMA, HCC
Nivolumab  SCLC etc.
Pembrolizumab  Gastric etc.
Avelumab  BLADDER
Aldesleukin  MELANOMA

THYROID: no drugs
PROSTATE: no drugs
BCC: no drugs





